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Which surgical procedure for weight
loss is performed most often in the US
today?
A. Gastric banding
B. Sleeve gastrectomy
C. Roux‐en‐Y gastric
bypass
D. Revision
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Patients who have had a weight loss
surgery procedure should not take
NSAIDS.
A. True
B. False
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Which of the following weight loss
medications is not approved for long
term use?

A. phentermine
ER/topirimate ER
(Qsymia)
B. lorcaserin (Belviq)
C. liraglutide (Saxenda)
D. phentermine
(Adipex)

5

Objectives
• Describe the bariatric pre‐surgical, surgical
and post‐surgical processes
• Perform long‐term primary care management
of post‐bariatric surgery patients
• Describe the use of the currently available
weight loss medications
6

2

Prevalence of Self-Reported Obesity Among U.S.
Adults by State and Territory, BRFSS, 2014
Prevalence estimates reflect BRFSS methodological changes started in 2011. These estimates should not be
compared to prevalence estimates before 2011.

¶

*Sample size <50 or the relative standard error (dividing the standard error by the
prevalence) ≥ 30%.

Within Subsets of Patients with Overweight
and/or Obesity
Deranged endocrine and
immune responses

Sick Fat Disease (SFD) (Adiposopathy)
• Endocrine/metabolic:
‒ Elevated blood glucose
‒ Elevated blood pressure
‒ Dyslipidemia
‒ Other metabolic diseases

Abnormal and pathologic
physical forces

Fat Mass Disease (FMD)
• Biomechanical/structural:
‒ Stress on weight‐bearing joints
‒ Immobility
‒ Tissue compression (i.e., sleep
apnea, gastrointestinal reflux,
high blood pressure, etc.)
‒ Tissue friction (i.e., intertrigo,
etc.)

Reference/s: [1] [2] [3] [4] [5] [6] [7]
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Fat Mass Disease
Cardiovascular
• Congestive heart failure and cor pulmonale
• Varicose veins
• Thromboembolic events (i.e., pulmonary embolus, stroke, etc.)
• Hypertension (i.e., compression of kidney)
Pulmonary
• Dyspnea
• Obstructive sleep apnea
• Hypoventilation syndrome
• Pickwickian syndrome
• Asthma
Neurologic
• Intracranial hypertension (pseudotumor cerebri) due to increased intraabdominal pressure, sleep apnea, etc.
• Stroke (see “cardiovascular”)
• Nerve entrapment (i.e., meralgia paresthetica, carpal tunnel syndrome,
Reference/s: [17] [18]
etc.)
9
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Fat Mass Disease
Musculoskeletal
• Immobility
• Osteoarthritis (e.g. knees,
hips)
• Low back pain
Gastrointestinal
• Gastrointestinal reflux
• Hernias
Integument
• Stria distensae (skin
stretch marks)
• Stasis pigmentation
• Venous stasis ulcers
• Cellulitis

• Myalgias
• Altered center of gravity
• Impaired balance

• Skin tags
• Intertrigo (i.e. bacterial,
fungal skin fold
infections)
• Carbuncles
Reference/s: [17] [18]
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Adiposopathy (Sick Fat Disease)
Pathophysiology

•

Impaired adipogenesis

•

Adipocyte organelle dysfunction (endoplasmic reticulum,
mitochondria, etc.)

•

Increased circulating free fatty acids

•

Pathogenic adipose tissue endocrine responses

•

Pathogenic adipose tissue immune responses

•

Pathogenic consequences to other body organs such as
fatty liver, vasculopathies (endothelial dysfunction,
atherosclerosis, hypercoagulation), etc.
Reference/s: [4] [6] [19] [20]
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Adiposopathy (Sick Fat Disease)
Anatomic Abnormalities

•

Adipocyte hypertrophy

•

Increased visceral, pericardial, perivascular, and other periorgan adiposity

•

Growth of adipose tissue beyond vascular supply

•

Increased adipose tissue immune cells

•

“Ectopic” fat deposition in other body organs (liver, muscle,
possibly pancreas, etc.)

Reference/s: [4] [6] [19] [20]
12
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Adiposopathy (Sick Fat Disease)
Other Body Organs
Adiposopathy most often results in metabolic disease when
accompanied by:
• Dysfunction other body organ
• Limitations in the metabolic “flexibility” of other body organs
Metabolic health is dependent upon the interactions or
crosstalk with adipose tissue and other body organs:
• Liver
• Muscle
• Pancreas
• Immune system
• Heart and vasculature
• Brain
• Endocrine glands
Reference/s: [4] [6] [19] [20]
• Intestine
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• Other body organs

Adiposopathy (Sick Fat Disease)
Clinical Manifestations
•
•

•
High blood glucose (prediabetes
mellitus, type 2 diabetes mellitus) •
High blood pressure
•

•

Metabolic syndrome

•

Adiposopathic dyslipidemia
‒ Increased triglyceride levels
‒ Decreased high-density
lipoprotein cholesterol levels

Hyperuricemia and gout
Cholelithiasis

•

Acanthosis Nigricans

•

Nephrolithiasis

•

Glomerulopathy

‒ Increased proportion of small,
dense, low-density lipoprotein
•
particles

‒ Increased lipoprotein-remnant
lipoproteins

Hepatosteatosis (fatty liver)

•

•
‒ Increased atherogenic particle
•
number (increased
apolipoprotein B)

‒ Increased triglyceride-rich
lipoproteins

Insulin resistance

•

Pro-thrombotic predisposition
Neuropsychiatric diseases (such as
worsening depression due to
adiposopathic immune and
endocrine responses)
Asthma (due to adiposopathic
immune and endocrine responses)
Worsening of other inflammatory
diseases (osteoarthritis,
atherosclerosis, etc.)

Reference/s: [3] [4] [6] [7] [21]
14

Eat Fewer Calories than you Burn = Lose Weight
Simple?

Obesity
pages S1‐S26, 7 JUL 2015 DOI: 10.1002/oby.21140
http://onlinelibrary.wiley.com/doi/10.1002/oby.21140/full#oby21140‐fig‐0004
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Please Respond…Obesity often occurs when
eating is used as a form of compensation for
lack of love or attention.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
16

Elements of Intensive Lifestyle Management
1) Food Plan (Multiple methods are effective)
• Restrict/reduce intake of certain food types (low
carbohydrate for metabolic syndrome, low fat)

• Set a caloric goal (1,200‐1,500 kcal/day for women,
1,500‐1,800 kcal/day for men, adjusted for body
weight)
• Specify a caloric deficit (500 or 750 kcal/ day)
• Consider patient preferences and health status when
iden fying a diet―a variety of approaches can
produce weight loss

17

Elements of Intensive Lifestyle Management
2) Increased Physical Activity
• Start with where they are and increase, either
duration or intensity

Ideal Plan
– Aerobic activity > 150 min/week for weight loss
– Resistance training to preserve lean mass
– Stretching/Flexibility
– Balance/Core
18
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Elements of Intensive Lifestyle Management
3) Behavioral Interventions ‐ critically important
Ideal
• Face‐to‐face sessions (≥14 with a
trained interventionist over the first 6 months)
• Maintain efforts over 1 year
• Incorporate strategies such as goal‐ setting and
self‐monitoring
• May need to refer to a counselor
19

CMS Coverage for
Intensive Behavioral Therapy
• For Medicare beneficiaries with obesity, who are
competent and alert at the time that counseling is
provided and whose counseling is furnished by a
qualified primary care physician or other primary care
practitioner and in a primary care setting, CMS covers:
• One face‐to‐face visit every week for the first month;
• One face‐to‐face visit every other week for months 2‐6;
• One face‐to‐face visit every month for months 7‐12, if
the beneficiary meets the 3kg weight loss requirement
during the first six months as discussed below.
https://www.cms.gov/Outreach‐and‐Education/Medicare‐Learning‐Network‐
MLN/MLNMattersArticles/downloads/MM8874.pdf
20

Adjunct Therapies or Tools

Obesity
pages S1‐S26, 7 JUL 2015 DOI: 10.1002/oby.21140
http://onlinelibrary.wiley.com/doi/10.1002/oby.21140/full#oby21140‐fig‐0002
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Misperception‐Surgery is a Cop‐out
Truth:
• Individuals affected by obesity are resistant to
long‐term weight loss by diet and exercise for a
variety of physiological reasons
• Surgery is a tool that impacts the gut‐brain‐
adipose tissue hormonal cycle
Adapted from ASMBS website

22

Misperception: Most people who have
metabolic surgery regain their weight
Truth:
• “Successful” weight loss is a loss of at least 50% of
excess body weight and the impact on quality of
life
• Longitudinally, most surgical patients maintain
their weight loss
• Up to 50% may regain some weight (5%) two or
more years after surgery
Adapted from ASMBS website
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Misconception: Metabolic surgery is
very dangerous
Truth:
• Risk of death within 30 days is 0.13 %; less
than cholecystectomy and hip replacement
• Multiple studies have now shown that the
benefits of bariatric surgery far outweigh the
risks as compared to those who did not have
surgery
Adapted from ASMBS website
24
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Misconception: Bariatric surgery causes
serious vitamin and mineral deficiencies
Truth:
• Malabsorption can cause deficiencies and are
totally avoidable with current
recommendations
• The current guidelines are increasingly
evidence‐based and simpler than in the past
Adapted from ASMBS website
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Please Respond…In many cases, obesity is
the result of a biological disorder.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
26

Bariatric Surgery in U.S. ‐ 2015
Total Procedures: 179,000
Sleeve gastrectomy
RYGB
Revisions
Gastric banding
Other

51%
27%
11.5%
9.5%
1%

27
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Definition of Success
•
•
•
•
•
•
•
•

50% Excess Body Weight (EBW) lost
Fewer chronic illnesses
Decreased number of medications taken
No more CPAP
Quality of Life improvements
Can walk one mile
My entire life will be better
REALISTIC EXPECTATIONS
28

Most Common Surgical Procedures
Sleeve gastrectomy
(sleeve)

Roux‐en‐Y gastric bypass
(RYGB or bypass)

29

Requirements‐Insurance Specific
• Plan exclusions
• Center of Excellence?
• 3 or 6 month program
– Can be done by multiple independent providers,
or
– Via Interdisciplinary team/Center

• Frequent changes to requirements
30
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Pre‐operative Recommendations
Clinical Practice Guidelines
• Complete H & P
– assess co‐morbidities, weight loss history,
commitment, exclusions for surgery

• Lab
– CMP, lipid profile, CBC, HgbA1C
– iron studies, B12, folic acid, 25‐hydroxyvitamin D
– additional evaluation as indicated

• Identify and optimize the most common obesity‐
related conditions
Adapted from Surgery for Obesity and Related Diseases 9(2013) 159‐191
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Pre‐operative Recommendations
Clinical Practice Guidelines
• Nutrition evaluation by a Registered Dietician
– Ability to incorporate nutritional and behavioral changes

• Psychosocial‐behavioral evaluation
– Active psych illness, substance abuse

• Pregnancy counseling
– Avoid pre‐op and 12‐18 months post‐op

• Tobacco cessation counseling
– smoking leads to poor wound healing
32

Pre‐operative Recommendations
Consider
• Cardiopulmonary evaluation
– polysomnography, ECG, additional evaluation if
cardiac disease or pulmonary hypertension suspected

• GI evaluation
– H.pylori screening in high prevalence areas
– gallbladder evaluation
– upper endoscopy if clinically indicated
• Abdominal pain from non‐surgical causes can be challenging
to diagnose
33
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Pre‐operative Recommendations
Clinical Practice Guidelines
• Age‐ and risk‐appropriate cancer screening
– Surgeons count on the PCP

• Weight loss via medical nutrition therapy
– Benefit not clear except in pt with diabetes
– Often done 2 weeks pre‐op
– Can reduce liver volume
– Can improve access for laparoscopic procedure
34

Please Respond…Obesity is usually
caused by overeating.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
35

Post‐surgery
• Avg. 1‐2 nights in hospital
• Avg. 2 weeks out of work
• Diet advanced from clears, full liquids, to purees
– Most recommend about one month to regular food
– Adequate hydration (usually > 1.5 L/day)

• Adjust postoperative medications, as needed
– Diabetes meds should be decreased at discharge
• Metformin should be continued

– Blood sugar monitoring critical in first weeks
– Hypertension meds require close attention
36
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Post‐operative Care
Usually done by the surgeon:

1, 3 months
– CBC, CMP

6 months
– CBC, CMP, lipids,
– B12 (if supplemented), 25‐vitamin D‐OH, folic acid, iron
studies, iPTH
– 24 hour urine calcium
37

Post‐surgery and Ongoing
Recommendations
• Two multivitamins/day or one bariatric vitamin
• Calcium citrate 1200‐1500 mg/day
• B12 1000 mcg/day (PO or intranasal)
• Elemental iron 45‐60 mg/day
• Vitamin D3, at least 3000 IU/day (titrate to
>30ng/mL)
Surgery for Obesity and Related Diseases 9 (2013) 159‐191
38

Ongoing Care
• Avoid NSAIDs
• Avoid pregnancy for 12‐18 months
Support dietary, behavioral, and physical activity changes
and recommendations
– Support groups (program provided)
– Behavioral counseling (refer if indicated)
– Physical activity (it is important!)

39
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Ongoing Care
Most surgeons/programs try to follow patients
for at least five years, but patients sometimes
stop going.

Annually
• lipid profile, CMP, CBC, 25‐ vitamin D‐OH, B12,
folic acid, iron studies, iPTH
• 24‐hour urinary calcium
• Bone density (DXA) at 2 years post surgery
40

Check if Symptomatic
Symptoms
Unexplained anemia, fatigue, persistent
diarrhea, cardiomyopathy, metabolic
bone disease

Check level
selenium

Hair loss (after first year), pica, dysgeusia,
erectile dysfunction

zinc

Anemia, neutropenia, myeloneuropathy,
impaired wound healing

copper

Excessively rapid weight loss, protracted
vomiting, excessive alcohol use,
neuropathy or encephalopathy or heart
failure

thiamine
41

Please Respond…Most obese people cause
their problem by not getting enough exercise.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
42
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Lap Band
• Band needs to be filled to create
restriction/lead to weight loss
• Reflux is common, but should be evaluated
with upper GI
• Many more complications than anticipated for
the “least invasive” procedure
44

Laparoscopic Adjustable Gastric Banding
A surgical procedure where an adjustable band is placed around the upper
stomach creating a small pouch. The band diameter is adjustable through
introduction of saline via a subcutaneous port that can be accessed from the
upper abdomen.

General
• Outpatient procedure
• Recovery usually one
week
• Contra‐indications:
‒ Poor surgical
candidate
‒ Severe physical
disorder
‒ Intolerance to
general anesthesia
‒ Pregnancy
‒ Drug or alcohol
addiction
‒ Untreated
esophagitis

Potential Acute
Complications

Potential Chronic
Complications

• Band too tight with
gastrointestinal
obstructive symptoms
(i.e., dysphagia)
• Leakage of gastric
contents into abdomen
• Hemorrhage
• Gastrointestinal bleeding
• Infection
• Cardiac dysrhythmias
• Atelectasis and
pneumonia
• Deep vein thrombosis
• Death

• Weight regain or no weight
loss
• Band slippage, erosion,
ulceration, port infection,
disconnection, and
displacement
• Esophageal dilation
• Rare nutrient deficiencies if
persistent vomiting or
marked and sustained
decrease in nutritional
intake
• Depression
• Potential need to re‐
45
operate
Reference/s: [5] [177] [178]
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Sleeve Gastrectomy
A surgical procedure wherein the stomach is reduced to about 25 percent of its original
size by the surgical removal of a large portion of the stomach along the greater
curvature, resulting in a narrower sleeve or tube-like structure.

Potential Acute Complications

General
• Hospital stay = 1‐2 days
• Recovery = 1‐2 weeks
• Contra‐indications:
‒ Poor surgical candidate
‒ Severe psychiatric disorder
‒ Intolerance to general anesthesia
‒ Pregnancy
‒ Drug or alcohol addiction
‒ Untreated or severe esophagitis
‒ Barrett’s esophagus
‒ Severe gastroparesis
‒ Achalasia
‒ Previous gastrectomy
‒ Previous gastric bypass
‒ Sometimes used as a staged
approach to gastric bypass

•
•
•
•
•
•
•
•
•
•
•
•

Gastrointestinal obstruction
Hemorrhage
Gastrointestinal bleeding
Anastomotic staple line leaks
Infection
Cardiac dysrhythmias
Atelectasis and pneumonia
Deep vein thrombosis
Pulmonary emboli
Rhabdomyolysis
Dehydration
Death

Reference/s: [5] [178] [179]
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Sleeve Gastrectomy
Potential Chronic Complications
• Weight regain or lack of long‐term
weight loss
• Marginal ulcers
• Esophageal dilation
• Dumping syndrome with reactive
hypoglycemia
• Small bowel obstruction caused by
internal hernias or adhesions
• Luminal stenoses (stomal narrowing)
• Anastomotic staple‐line leak
• Fistula formation
• Gallstones
• Calcium deficiency
• Secondary hyperparathyroidism
• Iron deficiency
• Protein malnutrition

• Other nutritional and mineral
deficiencies (i.e., deficiencies of vitamins
A, C, D, E, B, and K, folate, zinc,
magnesium, thiamine, etc.)
• Anemia (often related to mineral and
nutrition deficiencies)
• Metabolic acidosis
• Bacterial overgrowth
• Kidney stones (oxalosis)
• Neuropathies (resulting from nutritional
deficiencies)
• Osteoporosis (often caused by calcium
deficiency and chronically elevated
parathyroid hormone levels)
• Depression
• Potential need to re‐operate
Reference/s: [5] [178] [179]
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Gastric Bypass
A surgical procedure wherein the stomach is divided into a large residual
section and a smaller section (pouch) that is attached to a limb of the small
intestine at variable distances from the first part of the small intestine, largely
bypassing the stomach and part of the duodenum.

General
• Hospital stay = 2‐4 days
• Recovery = 1‐2 weeks
• Contra‐indications:
‒Poor surgical candidate
‒Severe psychiatric disorder
‒Intolerance to general
anesthesia
‒Pregnancy
‒Drug or alcohol addiction
‒Untreated esophagitis
‒Unwillingness or an inability
for appropriate long‐term
follow up

•
•
•
•
•
•
•
•
•
•
•
•

Potential Acute Complications
Gastrointestinal obstruction
Hemorrhage
Gastrointestinal bleeding
Anastomotic leaks
Infection
Cardiac dysrhythmias
Atelectasis and pneumonia
Deep vein thrombosis
Pulmonary emboli
Rhabdomyolysis
Dehydration
Death
Reference/s: [5] [177] [178] [179]
48

16

Gastric Bypass
Potential Chronic Complications
•
•
•
•
•
•
•
•
•
•
•
•
•

Weight regain
Marginal ulcers
•
Esophageal dilation
•
Dumping syndrome with reactive
hypoglycemia
Small bowel obstruction caused by
•
internal hernias or adhesions
Anastomotic stenoses (stomal narrowing)
•
Gallstones
Calcium deficiency
•
Secondary hyperparathyroidism
Bacterial overgrowth
Kidney stones (oxalosis)
•
Metabolic acidosis
•
Iron deficiency

Protein malnutrition
Other nutritional and mineral
deficiencies (i.e., deficiencies of vitamins
A, C, D, E, B, and K, folate, zinc,
magnesium, thiamine, etc.)
Anemia (often related to mineral and
nutrition deficiencies)
Neuropathies (resulting from nutritional
deficiencies)
Osteoporosis (often caused by calcium
deficiency and chronically elevated
parathyroid hormone levels)
Depression
Potential need to re‐operate
Reference/s: [5] [177] [178] [179]
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Comparison of Outcomes for Bariatric Surgical Procedures
Outcome

Overall

Excess body weight lost (%) median*
1 to 2 years
60 to 70
3 to 6 years
50 to 60
7 to 10 years
50
Remission of diabetes
mellitus
< 1 year
80
1 to 3 years
72
15 years
30
Mortality
 30 days (%)
0.08
> 30 days (%)
0.31
7-15 years

Sleeve
gastrectomy

RYGB

33 to 85
46 to 66
NA

48 to 85
53 to 77
25 to 68

56 to 68
80
NA

56 to 84
46 to 81
NA

0.296
0.11-0.34

0.20 to 0.50
0.14-0.21

30 to 40% lower than those not having surgery

NA = not available
*Excess body weight is the total preoperative weight minus ideal weight.
Multiple references, available.
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New Procedures
FDA Approval 8/15 (for patients with BMI of 30‐40)
– ORBERA™ and
– ReShape™ Intragastric Balloons

Short term, no ghrelin suppression
ASMBS views these balloon devices as a bridge
between medications and bariatric surgery

51
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Revisional Procedures
Surgical
• Band to sleeve or RYGB
• Sleeve to RYGB (for refractory reflux)
• Sleeve plus duodenal switch
• Revision of RYGB (older pouches were larger)
• Band over bypass (uncommon)
Non‐surgical: ROSE, StomaphyX endoscope procedure
–Not very effective

Experimental: lap band plus gastric plication
52

Please Respond…Most obese people
eat more than non‐obese people.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
53

Adjunct Therapies/

TOOLS

Obesity
pages S1‐S26, 7 JUL 2015 DOI: 10.1002/oby.21140
http://onlinelibrary.wiley.com/doi/10.1002/oby.21140/full#oby21140‐fig‐0002

54
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Medication and
Obesity
First, Do No Harm
55

Identify and Manage Concomitant
Pharmacotherapy That Might Alter Body Weight
Cardiovascular Medications
May increase body weight
• Some beta‐blockers
‒ Propranolol
‒ Atenolol
‒ Metoprolol
• Dihydropyridine (“dipine”)
calcium channel blockers
‒ Nifedipine
‒ Amlodipine
‒ Felodipine

Diabetes Mellitus Medications
May increase body weight
• Most insulins
• Sulfonylureas
• Thiazolidinediones
• Meglitinides
May decrease body weight
• Metformin
• Glucagon‐like peptide‐1
agonists
• Sodium glucose co‐
transporter 2 inhibitors
• Alpha glucosidase inhibitors
Reference/s: [7] [18] [57] [69]
56

Identify and Manage Concomitant
Pharmacotherapy That Might Alter Body Weight

Hormones
May increase body weight
• Glucocorticoids
• Estrogens
May decrease body weight
• Progestins
• Testosterone

Anti‐seizure Medications
May increase body weight
• Carbamazepine
• Gabapentin
• Valproate
May decrease body weight
• Lamotrigine
• Topiramate
• Zonisamide

Reference/s: [18] [57] [73] [74] [75] [76]
57
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Identify and Manage Concomitant
Pharmacotherapy That Might Alter Body Weight
Mood Stabilizers
May increase body weight
• Gabapentin
• Lithium
• Valproate
• Vigabatrin
Variable/neutral effects on body weight
• Carbamazepine (sometimes
reported to increase body
weight)
• Lamotrigine (sometimes
reported to decrease body
weight)
• Oxcarbazepine

Migraine Medications
May increase body weight
• Amitriptyline
• Gabapentin
• Paroxetine
• Valproic acid
• Some beta‐blockers
May decrease body weight
• Topiramate

Reference/s: [18] [57] [73] [74] [75] [76]
58

Identify and Manage Concomitant
Pharmacotherapy That Might Alter Body Weight
Antipsychotics
May substantially increase body weight
• Clozapine
• Olanzapine
• Zotepine
May somewhat increase body weight
• Asenapine
• Chlorpromazine
• Iloperidone
• Paliperidone
• Quetiapine
• Risperidone
• Sertindole
• Lithium
Variable/neutral effects on body weight
• Amisulpride
• Aripiprazole
• Haloperidol
• Lurasidone
• Ziprasidone

Hypnotics
May increase body weight
• Diphenhydramine
May have limited effects on body weight
• Benzodiazepines
• Melatonergic hypnotics
• Trazodone

Reference/s: [18] [57] [73] [74] [75]
59

Identify and Manage Concomitant
Pharmacotherapy That Might Alter Body Weight
Human Immunodeficiency
Virus (HIV) Medications
May increase body weight
• Some highly active antiretroviral
therapies (HAART) protease
inhibitors without HIV
lipodystrophy

Chemotherapies
May increase body weight
• Tamoxifen
• Cyclophosphamide
• Methotrexate
• 5‐fluorouracil
• Aromatase inhibitors
• Corticosteroids

May decrease body weight
• Some highly active antiretroviral
therapies (HAART) protease
inhibitors with HIV
lipodystrophy
Reference/s: [18] [57] [73] [74] [75]
60
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Please Respond…The majority of obese people
have poor eating habits that lead to their obesity.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
61

Anti-obesity Medications
Adjunct to nutritional, physical activity, and behavioral therapies
Objectives:
• Treat disease
‒ Adiposopathy or sick fat disease (SFD)
‒ Fat mass disease (FMD)
• Facilitate management of eating behavior
• Slow progression of weight gain/regain
• Improve the health, quality of life, and body weight of
the patient with overweight or obesity

Reference/s: [55] [159]
62

Pathologic Metabolic and/or Fat Mass
Consequences of Increased Body Fat

•

5-10 percent weight loss may improve adipocyte and
adipose tissue metabolic and immune function
– 5-10 percent weight loss may improve metabolic disease

•

5-10 percent weight loss may improve abnormal and
pathologic physical and mechanical forces
– 5-10 percent weight loss may improve fat mass diseases

Reference/s: [8] [160] [161]
63

21

When to Prescribe Medication for the
Treatment of Obesity
• History of difficulty achieving and maintaining
weight loss with life style intervention alone
(diet, physical activity, behavior change still need to happen)

• Sufficient health risk to justify Tx with a med
• BMI 30 or more or 27 with comorbidity
• For weight maintenance
• No contraindication
64

How to Choose?
• Consider medical history and current
medications
• Shared decision making
• Medical conditions (diabetes, depression, migraines,
CVD, HTN, glaucoma)

• Potential for pregnancy
• Certain amount of trial and error

• Insurance coverage/financial

65

Pharmacotherapy
Examples of anti‐obesity
medications approved 1999 or
before
•
•
•
•
•

Phentermine
Diethylpropion
Phendimetrazine
Benzphetamine
Orlistat

Examples of anti‐obesity
medications approved 2012 and
beyond
• Lorcaserin
• Phentermine HCL/topiramate
extended release
• Naltrexone HCL/bupropion HCL
extended release
• Liraglutide

Reference/s: [500] [502]
66
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Sympathomimetics
Approved for Short Term
Drug‐generic

Dosage

Mech of
Action

Common Side
Effects

Contraindications

Phentermine
(DEA class IV)
‐longest ½ life

AdipexP 37.5 mg
Ionamin 30 mg
15‐37.5 mg/d

Norepi‐
releasing
agent

Headache,
elev BP/HR,
insomnia, dry
mouth,
constipation,
palpitations,
changes in
libido

Anxiety disorders,
history of heart
disease, uncontrolled
HTN, seizure MAO
inh, preg,
hyperthyroidism,
glaucoma, history of
drug abuse

Diethylpropion Tenuate 75mg SR
(DEA class IV)
1x/day
‐shorter ½ life 25mg 3x/day

Norepi‐
releasing
agent

Similar to
above,
different pt
response

Similar to above

Phendiametra‐ Bontril 105mg SR
zine
36 mg. 2‐3x/day
(DEA class III)

Norepi‐
releasing,
dopaminergic

Similar

Similar to above
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Please Respond…Obesity is rarely
caused by a lack of willpower.
A.
B.
C.
D.
E.
F.
G.

Strongly Disagree
Disagree
Somewhat Disagree
Neutral
Somewhat Agree
Agree
Strongly Agree
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Medications Approved for Chronic Weight Management
Mechanism of
Action

Drug
Orlistat

(Xenical)

Lorcaserin

(Belviq)

Phentermine/
TopiramateER
(Qsymia)

Naltrexone/
BupropionSR
(Contrave)

Liraglutide 3.0 mg
(Saxenda)

Pancreatic lipase inhibitor
5‐HT2C serotonin agonist Little
affinity for other serotonergic
receptors
Sympathomimetic
Anticonvulsant (GABA
receptor modulation,
carbonic anhydrase inhibition,
glutamate antagonism)
Opioid receptor antagonist
Dopamine/noradrenaline
reuptake inhibitor

GLP‐1 receptor agonist

Dosing
120 mg orally with each
meal containing fat
10 mg orally twice daily

Orally in the morning:
3.75 mg/23 mg × 14 days
7.5/46 mg ×14 days

Response
Evaluation
Not addressed in label
Stop if <5% loss at 12 weeks

At 12 weeks, op on to ↑ to
11.25 mg/69 mg × 14 days,
then 15 mg/96 mg;
Stop if <5% loss at 12 weeks
on top dose
Stop if <5% loss at 12 weeks

Orally1 tab (8 mg/90 mg)
1 in am × 1 week;
1 in am 1 in pm × 1 week;
2 in am 1 in pm × 1 week;
2 in am 2 in pm
Inject subcutaneously (any Stop if <4% weight loss at
time of day); Initiate at 0.6 16 weeks
mg per day × 1 week. In
weekly intervals, increase
the dose by 0.6 mg/week
until a dose of 3.0 mg is
69
reached
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Medications Approved for Chronic Weight Management:
Drug
Cost/mos.

Caution

Contraindicatio
ns

Side Effects

Orlistat
Xenical
120mg/$520
Alli
60mg/$50

↑cyclosporine exposure;
rare liver failure;
concomitant multivitamin
advised, gall bladder
disease, warfarin,
antiepileptic meds,

Chronic malabsorption;
cholestasis, pregnancy
and breastfeeding

All the symptoms of
steatorrhea (oily
spotting, flatulence with
discharge, increased
defecation, etc.)

Lorcaserin
$240

SSRI, SNRI/MAOI, St. John’s
wort, triptans, buproprion,
dextromethorphan,
priapism, hypoglycemia if
on other antidiabetic meds

Pregnancy and
breastfeeding

Headache, nausea, dry
mouth, dizziness,
fatigue, constipation

Phentermine/
TopiramateER
$205

Fetal toxicity; acute myopia;
cognitive dysfunction;
metabolic acidosis;
hypoglycemia

Glaucoma; active
suicidal ideation,
hyperthyroidism;
MAOIs; pregnancy and
breastfeeding

Insomnia,
paraesthesias,
dysgeusia, dizziness, dry
mouth
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Medications Approved for Chronic Weight Management
Drug
Cost/mos.

Caution

Contraindications

Side Effects

Naltrexone/
Bupropion SR
$110

Suicidality, BP, HR,↑
seizure risk, glaucoma,
hepatotoxicity

Seizure disorder,
uncontrolled HTN,
chronic opioid use,
MAOIs, Pregnancy and
breastfeeding

Nausea,
vomiting,
headache,
dizziness,
insomnia

Liraglutide
3.0mg
$1200

Thyroid c‐cell tumors in
rodents, acute
pancreatitis, acute
gallbladder disease,
serious hypoglycemia if
used with insulin
secretagogue, heart rate
increase; use caution in
renal impairment;
hypersensitivity reactions

Patients with a personal
or family history of
medullary thyroid
carcinoma or Multiple
Endocrine Neoplasia,
Pregnancy and
breastfeeding

Nausea,
vomiting,
diarrhea,
constipation,
dyspepsia,
abdominal pain
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Eat Fewer Calories than you Burn = Lose Weight
Simple?

Obesity
pages S1‐S26, 7 JUL 2015 DOI: 10.1002/oby.21140
http://onlinelibrary.wiley.com/doi/10.1002/oby.21140/full#oby21140‐fig‐0004
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Please Respond…People can be addicted to
food, just as others are addicted to drugs, and
these people usually become obese.
A. Strongly Disagree
B. Disagree
C. Somewhat Disagree
D. Neutral
E. Somewhat Agree
F. Agree
G. Strongly Agree
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Weight Bias
• We all have bias
• First, we must recognize it
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Which surgical procedure for weight
loss is performed most often in the US
today?
A. Gastric banding
B. Sleeve gastrectomy
C. Roux‐en‐Y gastric
bypass
D. Revision
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Patients who have had a weight loss
surgery procedure should not take
NSAIDS.
A. True
B. False
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Which of the following weight loss
medications is not approved for long
term use?

A. phentermine
ER/topirimate ER
(Qsymia)
B. lorcaserin (Belviq)
C. liraglutide (Saxenda)
D. phentermine
(Adipex)
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Questions?
Robin.Schroeder@lvhn.org
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